Business
Beyfortus approved in US for infant RSV prevention
Beyfortus approved in US for infant RSV prevention.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n \n \n17 July 2023\n \nBeyfortus approved in the US for the prevention of RSV\nlower respiratory tract disease in infants\n \nFirst preventive option specifically designed to protect\nthe broad infant population through its first RSV season\n \nAcross all clinical endpoints, a single dose of Beyfortus delivered consistent and sustained efficacy against RSV disease vs placebo\n \nAstraZeneca and Sanofi's Beyfortus (nirsevimab) has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus will be available in the US ahead of the upcoming 2023-2024 RSV season.\n \nThe approval by the Food and Drug Administration (FDA) follows the unanimous vote by the Antimicrobial Drugs Advisory Committee (AMDAC) on the favourable benefit-risk profile of Beyfortus, and was based on the extensive clinical development programme for Beyfortusspanning three pivotal late-stage clinical trials. Across all clinical endpoints, a single dose of Beyfortus demonstrated consistent efficacy against RSV LRTD extending through five months, the duration of a typical RSV season.1-4\n \nBeyfortus is the first preventive option approved to protect a broad infant population, including those born healthy at term, or preterm, or with specific health conditions that make them vulnerable to severe RSV disease. The single dose can be flexibly administered at the beginning of the RSV season or at birth for those born during the RSV season.\n \nIskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said: \"Beyfortus represents an opportunity for a paradigm-shift in preventing serious respiratory disease due to RSV across a broad infant population in the US. The science that Beyfortus is built on demonstrates AstraZeneca's continued leadership in addressing the needs of the most vulnerable populations and reducing the burden on healthcare systems.\"\n \nThomas Triomphe, Executive Vice President, Vaccines, Sanofi, said: \"Today's approval marks an unprecedented moment for protecting infant health in the U.S., following an RSV season that too...